Liraglutide Cancer Signal Puts Agency In Uncharted Review Territory
Approving Novo Nordisk's Victoza (liraglutide) for type 2 diabetes would require FDA to surmount a substantial hurdle in the thyroid cancer signal seen with the GLP-1 analog
Approving Novo Nordisk's Victoza (liraglutide) for type 2 diabetes would require FDA to surmount a substantial hurdle in the thyroid cancer signal seen with the GLP-1 analog